| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293726 | Gastroenterology | 2011 | 12 Pages |
Abstract
Plasma levels of sTNFR-2, but not CRP or IL-6, are associated with an increased risk of CRC. Anti-inflammatory drugs appear to reduce risk of CRC among women with high, but not low, baseline levels of sTNFR-2. Certain subsets of the population, defined by inflammatory markers, may obtain different benefits from anti-inflammatory drugs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Andrew T. Chan, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs,